Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Ann Marie Weideman, Marco Aurelio Tapia-Maltos, Kory Johnson, Mark Greenwood, Bibiana Bielekova, Ann Marie Weideman, Marco Aurelio Tapia-Maltos, Kory Johnson, Mark Greenwood, Bibiana Bielekova
Abstract
Objective: To perform a meta-analysis of randomized, blinded, multiple sclerosis (MS) clinical trials, to test the hypothesis that efficacy of immunomodulatory disease-modifying therapies (DMTs) on MS disability progression is strongly dependent on age.
Methods: We performed a literature search with pre-defined criteria and extracted relevant features from 38 clinical trials that assessed efficacy of DMTs on disability progression. We fit a linear regression, weighted for trial sample size, and duration, to examine the hypothesis that age has a defining effect on the therapeutic efficacy of immunomodulatory DMTs.
Results: More than 28,000 MS subjects participating in trials of 13 categories of immunomodulatory drugs are included in the meta-analysis. The efficacy of immunomodulatory DMTs on MS disability strongly decreased with advancing age (R2 = 0.6757, p = 6.39e-09). Inclusion of baseline EDSS did not significantly improve the model. The regression predicts zero efficacy beyond approximately age 53 years. The comparative efficacy rank derived from the regression residuals differentiates high- and low-efficacy drugs. High-efficacy drugs outperform low-efficacy drugs in inhibiting MS disability only for patients younger than 40.5 years.
Conclusion: The meta-analysis supports the notion that progressive MS is simply a later stage of the MS disease process and that age is an essential modifier of a drug efficacy. Higher efficacy treatments exert their benefit over lower efficacy treatments only during early stages of MS, and, after age 53, the model suggests that there is no predicted benefit to receiving immunomodulatory DMTs for the average MS patient.
Keywords: clinical practice; clinical trials; meta-analysis; neuroimmunology; neuroinflammation.
Figures
References
- Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci (2012) 13:507–14.10.1038/nrn3275
- Komori M, Blake A, Greenwood M, Lin YC, Kosa P, Ghazali D, et al. CSF markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol (2015) 78:3–20.10.1002/ana.24408
- Montalban X, Hauser SL, Kappos L, Arnold D, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med (2017) 376:209–20.10.1056/NEJMoa1606468
- Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol (2012) 8:647–56.10.1038/nrneurol.2012.168
- Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain (2007) 130:1089–104.10.1093/brain/awm038
- Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol (2010) 68:477–93.10.1002/ana.22230
- Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain (2012) 135:2925–37.10.1093/brain/aws189
- Komori M, Lin YC, Cortese I, Blake A, Ohayon J, Cherup J, et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol (2016) 3:166–79.10.1002/acn3.293
- Komori M, Kosa P, Stein J, Zhao V, Blake A, Cherup J, et al. Pharmacodynamic effects of daclizumab in the intrathecal compartment. Ann Clin Transl Neurol (2017) 4:478–90.10.1002/acn3.427
- Wuest SC, Mexhitaj I, Chai NR, Romm E, Scheffel J, Xu B, et al. A complex role of herpes viruses in the disease process of multiple sclerosis. PLoS One (2014) 9:e105434.10.1371/journal.pone.0105434
- Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol (2011) 69:481–92.10.1002/ana.22109
- Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain (2012) 135:886–99.10.1093/brain/aws012
- Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol (2009) 8:280–91.10.1016/S1474-4422(09)70043-2
- Yang R, Dunn JF. Reduced cortical microvascular oxygenation in multiple sclerosis: a blinded, case-controlled study using a novel quantitative near-infrared spectroscopy method. Sci Rep (2015) 5:16477.10.1038/srep16477
- Lassmann H, Reindl M, Rauschka H, Berger J, Aboul-Enein F, Berger T, et al. A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain (2003) 126:1347–57.10.1093/brain/awg127
- McMahon JM, McQuaid S, Reynolds R, FitzGerald UF. Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis. Mult Scler (2012) 18:1437–47.10.1177/1352458512438455
- Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature (2017) 541:481–7.10.1038/nature21029
- International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 476:214–9.10.1038/nature10251
- Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain (2006) 129:595–605.10.1093/brain/awl313
- Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain (2006) 129:606–16.10.1093/brain/awl313
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 6:e1000097.10.1371/journal.pmed.1000097
- Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol (2009) 65:268–75.10.1002/ana.21606
- Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol (2014) 75:43–9.10.1002/ana.24018
- Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med (2012) 367:1087–97.10.1056/NEJMoa1206328
- R: A language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; (2016).
- RStudio: Integrated Development for R. [computer program]. Boston, MA: RStudio, Inc., (2015).
- Sheather SA. Modern Approach to Regression with R. New York: Springer; (2009).
- Knol MJ, Pestman WR, Grobbee DE. The (mis)use of overlap of confidence intervals to assess effect modification. Eur J Epidemiol (2011) 26:253–4.10.1007/s10654-011-9563-8
- Bielekova B, Tintore M. Sustained reduction of MS disability: new player in comparing disease-modifying treatments. Neurology (2016) 87:1966–7.10.1212/WNL.0000000000003314
- Miller AE, O’Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler (2012) 18:1625–32.10.1177/1352458512450354
- Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 256:405–15.10.1007/s00415-009-0093-1
- Devonshire V, Havrdova E, Radue EW, O’Connor P, Zhang-Auberson L, Agoropoulou C, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol (2012) 11:420–8.10.1016/S1474-4422(12)70056-X
- Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 66:460–71.10.1002/ana.21867
- Schwartz M. “Tissue-repairing” blood-derived macrophages are essential for healing of the injured spinal cord: from skin-activated macrophages to infiltrating blood-derived cells? Brain Behav Immun (2010) 24:1054–7.10.1016/j.bbi.2010.01.010
- Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci U S A (2004) 101:8180–5.10.1073/pnas.0402268101
- Bieber AJ, Kerr S, Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann Neurol (2003) 53:680–4.10.1002/ana.10578
- Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 64:1144–51.10.1212/01.WNL.0000156155.19270.F8
Source: PubMed